| Literature DB >> 19460458 |
John H Krystal1, David F Tolin, Gerard Sanacora, Stacy A Castner, Graham V Williams, Deane E Aikins, Ralph E Hoffman, D Cyril D'Souza.
Abstract
Current treatments for psychiatric disorders were developed with the aim of providing symptomatic relief rather than reversing underlying abnormalities in neuroplasticity or neurodevelopment that might contribute to psychiatric disorders. This review considers the possibility that psychiatric treatments might be developed that target neuroplasticity deficits or that manipulate neuroplasticity in novel ways. These treatments might not provide direct symptomatic relief. However, they might complement or enhance current pharmacotherapies and psychotherapies aimed at the prevention and treatment of psychiatric disorders. In considering neuroplasticity as a target for the treatment of psychiatric disorders, we build on exciting new findings in the areas of anxiety disorders, mood disorders, and schizophrenia.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19460458 PMCID： PMC2898127 DOI： 10.1016/j.drudis.2009.05.002
Source DB: PubMed Journal: Drug Discov Today ISSN： 1359-6446 Impact factor: 7.851